Granted Patent
B2
US 12,428,458 · App. 17/817,084 · Granted Sep 30, 2025
Therapeutic agent for psoriasis
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present inventors discovered that an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Based on these findings, pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the HMGB1 fragment peptide having the specific amino acid sequence are provided.
Claims (15)
1. A method of treating psoriasis, comprising administering to a patient with psoriasis an effective amount of a peptide selected from the group consisting of:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 1; and
(b) a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one or two additional amino acids and having an effect of suppressing erythema, thickening, and scaling of the skin in a subject with psoriasis.
2. The method of claim 1 , wherein the psoriasis is plaque psoriasis.
3. The method of claim 1 , wherein the peptide is selected from the group consisting of:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 1; and
(b) a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one additional amino acid and having an effect of suppressing erythema, thickening, and scaling of the skin in a subject with psoriasis.
4. The method of claim 1 , wherein the peptide is a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
5. A method of suppressing a skin symptom selected from the group consisting of erythema, thickening, scaling and desquamation in a patient with psoriasis, comprising administering to the patient an effective amount of a peptide selected from the group consisting of:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 1; and
(b) a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one or two additional amino acids and having an effect of suppressing erythema, thickening, and scaling of the skin in a subject with psoriasis.
6. The method of claim 5 , wherein the peptide is selected from the group consisting of:
(a) a peptide consisting of the amino acid sequence of SEQ ID NO: 1; and
(b) a peptide consisting of the amino acid sequence of SEQ ID NO: 1 with one additional amino acid and having an effect of suppressing erythema, thickening, and scaling of the skin in a subject with psoriasis.
7. The method of claim 5 , wherein the peptide is a peptide consisting of the amino acid sequence of SEQ ID NO: 1.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2022
From: TAMAI, KATSUTO; SHIMBO, TAKASHI
To: OSAKA UNIVERSITY
Reel/Frame 060753/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Aug 9, 2022
From: YAMAZAKI, TAKEHIKO
To: STEMRIM INC.
Reel/Frame 060753/0650 →
Priority Claims (1)
JP 2018-020687
· Feb 8, 2018
· national
Continuity (2)
Continuation
16967919
References Cited (400)
US 3896810A
· Akiyama
· 1975
[cited by applicant]
US 4732155A
· Zetter et al.
· 1988
[cited by applicant]
US 5133755A
· Brekke
· 1992
[cited by applicant]
US 5661127A
· Bhatnagar et al.
· 1997
[cited by applicant]
US 5760261A
· Guttag
· 1998
[cited by applicant]
US 5851986A
· Takada et al.
· 1998
[cited by applicant]
US 5902799A
· Herrmann et al.
· 1999
[cited by applicant]
US 6723319B1
· Ito et al.
· 2004
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 7220723B2
· Tracey et al.
· 2007
[cited by applicant]
US 7288250B2
· Newman et al.
· 2007
[cited by applicant]
US 7446100B2
· Pilarski
· 2008
[cited by applicant]
US 7470538B2
· Laughlin et al.
· 2008
[cited by applicant]
US 7585504B2
· Wu et al.
· 2009
[cited by applicant]
US 7632802B2
· Tessier et al.
· 2009
[cited by applicant]
US 7749959B2
· Tracey et al.
· 2010
[cited by applicant]
US 7829097B2
· Tsung et al.
· 2010
[cited by applicant]
US 7833975B2
· Okazawa
· 2010
[cited by applicant]
US 7939057B2
· Battista et al.
· 2011
[cited by applicant]
US 8114668B2
· Stolen et al.
· 2012
[cited by applicant]
US 8119121B2
· Fraser et al.
· 2012
[cited by applicant]
US 8551470B2
· Son et al.
· 2013
[cited by applicant]
US 8673580B2
· Tamai et al.
· 2014
[cited by applicant]
US 9623078B2
· Tamai et al.
· 2017
[cited by applicant]
US 9688733B2
· Tamai et al.
· 2017
[cited by applicant]
US 9919010B2
· Tamai et al.
· 2018
[cited by applicant]
US 20030003482A1
· Halle et al.
· 2003
[cited by applicant]
US 20030060410A1
· Tracey et al.
· 2003
[cited by applicant]
US 20040031072A1
· La Rosa et al.
· 2004
[cited by applicant]
US 20040156851A1
· Newman
· 2004
[cited by applicant]
US 20040191246A1
· Connelly et al.
· 2004
[cited by applicant]
US 20040242481A1
· Bianchi et al.
· 2004
[cited by applicant]
US 20040249448A1
· Gault
· 2004
[cited by applicant]
US 20040265971A1
· Sato et al.
· 2004
[cited by applicant]
US 20050014255A1
· Tang et al.
· 2005
[cited by applicant]
US 20050101564A1
· Pilarski
· 2005
[cited by applicant]
US 20060003312A1
· Blau et al.
· 2006
[cited by applicant]
US 20060035851A1
· Bianchi et al.
· 2006
[cited by applicant]
US 20060039896A1
· Kleinsek et al.
· 2006
[cited by applicant]
US 20060069064A1
· Khaldoyanidi
· 2006
[cited by applicant]
US 20060111287A1
· Bianchi
· 2006
[cited by applicant]
US 20060183667A1
· Jonassen et al.
· 2006
[cited by applicant]
US 20070154529A1
· Bullerdiek
· 2007
[cited by applicant]
US 20070238663A1
· Capogrossi et al.
· 2007
[cited by applicant]
US 20090062187A1
· Bianchi et al.
· 2009
[cited by applicant]
US 20090202500A1
· Tamai et al.
· 2009
[cited by applicant]
US 20100040608A1
· Wahren-Herlenius
· 2010
[cited by examiner]
US 20100280493A1
· Nayak
· 2010
[cited by applicant]
US 20110097309A1
· Tamai et al.
· 2011
[cited by applicant]
US 20120237504A1
· Brooks et al.
· 2012
[cited by applicant]
US 20200038486A1
· Tamai et al.
· 2020
[cited by applicant]
US 20200369736A1
· Tamai et al.
· 2020
[cited by applicant]
US 20210024594A1
· Tamai et al.
· 2021
[cited by applicant]
US 20210163552A1
· Nihashi et al.
· 2021
[cited by applicant]
US 20220009976A1
· Tamai et al.
· 2022
[cited by applicant]
US 20220265787A1
· Tamai et al.
· 2022
[cited by applicant]
AU 2003228099A1
· 2004
[cited by applicant]
AU 2004203732A1
· 2004
[cited by applicant]
AU 2007315073A1
· 2008
[cited by applicant]
AU 2012248676A1
· 2013
[cited by applicant]
CA 2325226A1
· 2001
[cited by applicant]
CA 2512512A1
· 2004
[cited by applicant]
CA 2636788A1
· 2008
[cited by applicant]
CN 1193092C
· 2005
[cited by applicant]
CN 1671742A
· 2005
[cited by applicant]
CN 1878793A
· 2006
[cited by applicant]
CN 101132811A
· 2008
[cited by applicant]
CN 101291955A
· 2008
[cited by applicant]
CN 100447154C
· 2008
[cited by applicant]
CN 101366728A
· 2009
[cited by applicant]
CN 101374538A
· 2009
[cited by applicant]
CN 101528266A
· 2009
[cited by applicant]
CN 101641372A
· 2010
[cited by applicant]
CN 102076350A
· 2011
[cited by applicant]
CN 102247392A
· 2011
[cited by applicant]
CN 102443064A
· 2012
[cited by applicant]
CN 103687946A
· 2014
[cited by applicant]
CN 102711777B
· 2015
[cited by applicant]
CN 104884076A
· 2015
[cited by applicant]
CN 104955470A
· 2015
[cited by applicant]
CN 105026553A
· 2015
[cited by applicant]
CN 107188948A
· 2017
[cited by applicant]
CN 110494154A
· 2019
[cited by applicant]
EP 1114862A2
· 2001
[cited by applicant]
EP 1459759A1
· 2004
[cited by applicant]
EP 0791601B1
· 2005
[cited by applicant]
EP 2039367A1
· 2009
[cited by applicant]
EP 2055308A1
· 2009
[cited by applicant]
EP 2284255A1
· 2011
[cited by applicant]
EP 2301559A1
· 2011
[cited by applicant]
EP 2301560A1
· 2011
[cited by applicant]
EP 2601971A1
· 2013
[cited by applicant]
EP 2703487A1
· 2014
[cited by applicant]
EP 2913059A1
· 2015
[cited by applicant]
EP 2913058B1
· 2017
[cited by applicant]
EP 2494977B1
· 2018
[cited by applicant]
EP 3556378A1
· 2019
[cited by applicant]
EP 3358011B1
· 2020
[cited by applicant]
EP 3719117A1
· 2020
[cited by applicant]
EP 3750553A1
· 2020
[cited by applicant]
JP 3018313B2
· 2000
[cited by applicant]
JP 2003505506A
· 2003
[cited by applicant]
JP 3421741B2
· 2003
[cited by applicant]
JP 2005508913A
· 2005
[cited by applicant]
JP 2005512507A
· 2005
[cited by applicant]
JP 2005537253A
· 2005
[cited by applicant]
JP 2006510619A
· 2006
[cited by applicant]
JP 2006517537A
· 2006
[cited by applicant]
JP 2006523085A
· 2006
[cited by applicant]
JP 2008507505A
· 2008
[cited by applicant]
JP 2008511300A
· 2008
[cited by applicant]
JP 2010503630A
· 2010
[cited by applicant]
JP 4982739B2
· 2012
[cited by applicant]
JP 5134772B2
· 2013
[cited by applicant]
JP 5814549B2
· 2015
[cited by applicant]
JP 7405345B2
· 2023
[cited by applicant]
KR 1020050054907A
· 2005
[cited by applicant]
KR 20090078304A
· 2009
[cited by applicant]
KR 101448800B1
· 2014
[cited by applicant]
KR 1020150103660A
· 2015
[cited by applicant]
KR 101636139B1
· 2016
[cited by applicant]
RU 2005102593A
· 2005
[cited by applicant]
RU 2410125C2
· 2011
[cited by applicant]
RU 2010148785A
· 2012
[cited by applicant]
RU 2599448C2
· 2016
[cited by applicant]
WO 0108683A1
· 2001
[cited by applicant]
WO 0234292A1
· 2002
[cited by applicant]
WO 02074337A1
· 2002
[cited by applicant]
WO 02088181A2
· 2002
[cited by applicant]
WO 02092004A2
· 2002
[cited by applicant]
WO 03026691A2
· 2003
[cited by applicant]
WO 03043651A1
· 2003
[cited by applicant]
WO 2004004763A2
· 2004
[cited by applicant]
WO 2004004770A1
· 2004
[cited by applicant]
WO 2004044001A1
· 2004
[cited by applicant]
WO 2004046345A2
· 2004
[cited by applicant]
WO 2004061456A2
· 2004
[cited by applicant]
WO 2005025604A2
· 2005
[cited by applicant]
WO 2005074984A1
· 2005
[cited by applicant]
WO 2005087797A1
· 2005
[cited by applicant]
WO 2006008779A1
· 2006
[cited by applicant]
WO 2006010628A1
· 2006
[cited by applicant]
WO 2006024547A2
· 2006
[cited by applicant]
WO 2006047820A1
· 2006
[cited by applicant]
WO 2006077614A1
· 2006
[cited by applicant]
WO 2006080434A1
· 2006
[cited by applicant]
WO 2006100651A1
· 2006
[cited by applicant]
WO 2006114805A2
· 2006
[cited by applicant]
WO 2007015546A1
· 2007
[cited by applicant]
WO 2007031100A1
· 2007
[cited by applicant]
WO 2007061762A2
· 2007
[cited by applicant]
WO 2007076200A2
· 2007
[cited by applicant]
WO 2007130725A2
· 2007
[cited by applicant]
WO 2008018641A1
· 2008
[cited by applicant]
WO 2008031612A1
· 2008
[cited by applicant]
WO 2008053892A1
· 2008
[cited by applicant]
WO 2008104090A1
· 2008
[cited by applicant]
WO 2008155659A2
· 2008
[cited by applicant]
WO 2009133939A1
· 2009
[cited by applicant]
WO 2009133940A1
· 2009
[cited by applicant]
WO 2009133943A1
· 2009
[cited by applicant]
WO 2011046570A1
· 2011
[cited by applicant]
WO 2011052668A1
· 2011
[cited by applicant]
WO 2012147470A1
· 2012
[cited by applicant]
WO 2014065347A1
· 2014
[cited by applicant]
WO 2014065348A1
· 2014
[cited by applicant]
WO 2014191364A1
· 2014
[cited by applicant]
WO 2016184795A1
· 2016
[cited by applicant]
WO 2016185476A1
· 2016
[cited by applicant]
WO 2018139562A1
· 2018
[cited by applicant]
WO 2018186480A1
· 2018
[cited by applicant]
WO 2018199107A1
· 2018
[cited by applicant]
WO 2019107530A1
· 2019
[cited by applicant]
WO 2019107566A1
· 2019
[cited by applicant]
WO 2019156137A1
· 2019
[cited by applicant]
WO 2020071519A1
· 2019
[cited by applicant]
WO 2020071520A1
· 2020
[cited by applicant]
WO 2020158924A1
· 2020
[cited by applicant]
WO 2021201260A1
· 2021
[cited by applicant]
Nickoloff et al. (J Clin Invest. 2004;113(12):1664-1675) (Year: 2004).
[cited by examiner]
Tamilselvi et al. (Scand J Immunol. Dec. 2013;78(6):545-53) (Year: 2013).
[cited by examiner]
Fujii, Makiko et al., “Roles of Bone Morphogenetic Protein Type I Receptors and Smad Proteins in Osteoblast and Chondroblast Differentiation.” Molecular Biology of the Cell, 10(11): 3801-3813, (Year: 1999).
[cited by applicant]
Fukushima, Norihide et al., “Registry Report on Heart Transplantation in Japan (Jun. 2016).” Circulation Journal, 81: 298-303, (Year: 2017).
[cited by applicant]
Funayama, Akira et al. “Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure.” Cardiovascular Research 99(4): 657-664, (Year: 2013).
[cited by applicant]
Gallina, Clara et al., “A New Paradigm in Cardiac Regeneration: The Mesenchymal Stem Cell Secretome.” Stem Cells International, vol. 2015, Article ID 765846, pp. 1-10, (Year: 2015).
[cited by applicant]
Germani, Antonia et al., “Pivotal Advance: High-mobility group box 1 protein-a cytokine with a role in cardiac repair.” Journal of Leukocyte Biology, 81(1): 41-45, (Year: 2007).
[cited by applicant]
Gong, Wei et al. “The Anti-Inflammatory Activity of HMGB1 A Box is Enhanced When Fused with C-Terminal Acidic Tail,” Journal of Biomedicine and Biotechnology, vol. 2010, Article ID 915234, pp. 1-6 (Year: 2010).
[cited by applicant]
Goto, et al., “Investigation of the application of myocardial regeneration inducing therapy using HMGB1 to cardiac infarction.” Regenerative Medicine, 16: 289, Feb. 1, 2017.
[cited by applicant]
Granero-Molto, F. et al., “Role of mesenchymal stem cells in regenerative medicine: application to bone and cartilage repair,” Expert Opinion on Biological Therapy, 8(3): 255-268, (Year: 2008).
[cited by applicant]
Gudjonsson, Johann E. & Elder, James T. “Chapter 18—Psoriasis.” Fitzpatrick's Dermatology in General Medicine, 8th edition, New York: Mc-Graw Hill Medical, 2012, pp. 197-217.
[cited by applicant]
Gueukdjian S. A. “Intra-Arterial Injections in the Treatment of Peripheral Vascular Disease.” Postgrad Medical Journal, 31(351): 30-31, (Year: 1955).
[cited by applicant]
Guillot, Loïc et al. “Response of Human Pulmonary Epithelial Cells to Lipopolysaccharide Involves Toll-like Receptor 4 (TLR4)-dependent Signaling Pathways.” Journal of Biological Chemistry, 279(4): 2712-2718, Nov. 4, 20…
[cited by applicant]
Guo, Haiwei H. et al. “Protein tolerance to random amino acid change.” Proceedings of the National Academy of Sciences 101(25):9205-9210, Jun. 22, 2004.
[cited by applicant]
Guo, Jing et al. “Monocyte Chemotactic Protein-1 Promotes the Myocardial Homing of Mesenchymal Stem Cells in Dilated Cardiomyopathy.” International Journal of Molecular Sciences, 14: 8164-8178, (Year: 2013).
[cited by applicant]
Harris, Helena Erlandsson & Raucci, Angela “Alarmin(g) news about danger,” EMBO Reports, 7(8): 774-778, Jul. 21, 2006.
[cited by applicant]
Harrison, Craig A. et al., “Oxidation Regulates the Inflammatory Properties of the Murine S100 Protein S100A8.” J. Biol. Chem., 274(13): 8561-8569, (Year: 1999).
[cited by applicant]
Healthwise Staff, “Age-related Macular Degeneration,” University of Michigan Health System, Aug. 2015, https:www.uofmhealth.org/health-library/hw176039.
[cited by applicant]
He, Y.T., et al., “HMGB1 Ameliorates Inflammatory Bowel Disease by Inducing Circulating Mesenchymal Stem Cells.” The 17th Congress of the Japanese Society for Regenerative Medicine, 2018, 34, Abstract.
[cited by applicant]
Heil, Matthias et al., “An engineered heparin-binding form of VEGF-E (hbVEGF-E),” Angiogenesis, 6(3): 201-211, (Year: 2003).
[cited by applicant]
Herrera, M.B. et al., “Exogenous mesenchymal stem cells localize to the kidney by means of CD44 following acute tubular injury,” Kidney International, 2: 430-441, (Year: 2007).
[cited by applicant]
Hiratsuka S. et al. “Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis,” Natural Cell Biology, 8(12): 1369-1375, Nov. 26, 2006.
[cited by applicant]
HMGBiotech, “BoxA from HMGB1, human & mouse, LPS-free.” HMGBiotech Srl, 2008, C.F. e P.IVA 04942740962, http://www.hmgbiotech.com/products.php?ID=91, ,accessed Jan. 27, 2017 from internet>.
[cited by applicant]
HMGBiotech, “BoxA from HMGB1, human & mouse, LPS-free-Datasheet.” HMGBiotech Srl, 2008, Via Moretto da Brescia 25, 20133—Milano, Italy, http://www.hmgbiotech.com/upload/documenti/0515122144_boxa.
[cited by applicant]
HNRPK_Human, Accession No. P61978, entry version 183, UniProtKB/Swiss-Prot, Sep. 12, 2018.
[cited by applicant]
Hori, Osamu et al. “The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin,” Journal of Biological Chemistry, 270(43): 25752-25761, (Year: 1995).
[cited by applicant]
Hornef, Mathias W., et al. “Toll-like Receptor 4 Resides in the Golgi Apparatus and Colocalizes with Internalized Lipopolysaccharide in Intestinal Epithelial Cells.” J. Exp. Med., 195(5): 559-570, (Year: 2002).
[cited by applicant]
Hruby, V.J., “Designing Peptide Receptor Agonists and Antagonists.” Nature Reviews Drug Discovery, 1: 847-858, Nov. 1, 2002.
[cited by applicant]
Hu, Zhen et al. “Role of high-mobility group box 1 protein in inflammatory bowel disease.” Inflammation Research 64(8): 557-563, (Year 2015).
[cited by applicant]
Huttunen, Henri J. et al. “Receptor for Advanced Glycation End Products-binding COOH-terminal Motif of Amphoterin Inhibits Invasive Migration and Metastasis,” Cancer Research, 62: 4805-4811, Aug. 15, 2002.
[cited by applicant]
Ichinose, Kunihiro et al., “Antiangiogenic Endostatin Peptide Ameliorates Renal Alterations in the Early Stage of a Type 1 Diabetic Nephropathy Model.” Diabetes, 54(10): 2891-2903, (Year: 2005).
[cited by applicant]
Instruction Manual of HiTrap chelating HP (Amersham Biosciences), 2003, pp. 1-6.
[cited by applicant]
Ishikane, Shin, “Therapeutic application of allogenic fetal membrane-derived mesenchymal stem cells transplantation in regenerative medicine.” Pharmaceutical Bulletin of Fukuoka University, 11(0): 17-25, (Year: 2011).
[cited by applicant]
Ishikane, Shin et al., “Development of multi-growth factor secreted fetal membrane-derived mesenchymal stem cell sheets.” Grants-in-Aid for Scientific Research, pp. 1-6, (Year: 2014).
[cited by applicant]
Jansen, Jan et al., “Transplantation of hematopoietic stem cells from the peripheral blood,” Journal of Cellular and Molecular Medicine, 9(1): 37-50, (Year: 2005).
[cited by applicant]
Jayaraman, Lata et al. “High mobility group protein-1 (HMG-1) is a unique activator of p53.” Genes & Development, 12(4): 462-472, (Year: 1998).
[cited by applicant]
Jiang, Yuehua et al. “Pluripotency of mesenchymal stem cells derived from adult marrow.” Nature, 418(6893): 41-49, (Year: 2002).
[cited by applicant]
Jiao, Chunhua et al., “Researchers find nerve damage may precede diabetic retinopathy,” EurekAlert! Science News, Apr. 2016, https://www.eurekalert.org/pub_releases/2016-04/uoih-rfv042616.php.
[cited by applicant]
Jin, Y. “Isolating culture and induced differentiation of marrow mesenchyma stem cells,” Principles and Protocols of Tissue Engineering, Jun. 2004, 277-278 (English translation attached).
[cited by applicant]
Justice, Monica J. & Dhillon, Paraminder “Using the mouse to model human disease: increasing validity and reproducibility.” Dis Model Mech. 9(2):101-103, Feb. 1, 2016.
[cited by applicant]
Kaneda et al., “Tissue repair mechanism by bone-marrow-derived stem cells.” Experimental Mediciner, 2013, 31(5): 655-661.
[cited by applicant]
Kaneko, Masahiro et al. “Abstract 11250: Bone Marrow Mononuclear Cell Transplantation Improves Cardiac Function in Ischemic Cardiomyopathy via High Mobility Group Box 1 Released from Dead Donor Cells.” Circulation 126:A…
[cited by applicant]
Kassis, I. et al. “Isolation of mesenchymal stem cells from G-CSF mobilized human peripheral blood using fibrin microbeads,” Bone Marrow Transplantation, 37(10): 967-976, (Year: 2006).
[cited by applicant]
Kawabata, Hideyuki et al., “High Mobility Group Box 1 Is Upregulated After Spinal Cord Injury and Is Associated With Neuronal Cell Apoptosis,” Spine, 35(11): 1109-1115, (Year: 2010).
[cited by applicant]
Kern, Susanne et al. “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue,” Stem Cells, 24(5): 1294-1301, (Year: 2006).
[cited by applicant]
Kessler, Michael W. & Grande, Daniel A. “Tissue Engineering and Cartilage.” Organogenesis, 4(1): 28-32, (Year: 2008).
[cited by applicant]
Kido, Takashi et al., “Abstract 15756: The Administration of High-morbidity Group Box 1 Fragment Prevents Deterioration of Cardiac Performance by Enhancement of Bone-marrow Mesenchymal Stem Cells Homing in the Delta-sar…
[cited by applicant]
Kikuchi, K. et al., “HMGB1 as a therapeutic target in spinal cord injury: A hypothesis for novel therapy development (Review),” Experimental and Therapeutic Medicine, 2: 767-770, (Year: 2011).
[cited by applicant]
Kikuchi, K. et al. “Systemic administration of HMGB1 improves bleomycin-induced skin fibrosis by locally accumulating bone marrow mesenchymal stem cells.” Regenerative Medicine, Feb. 1, 2017, 16: 422.
[cited by applicant]
Kim, Sang-Soo et al. “Skin Regeneration Using Keratinocytes and Dermal Fibroblasts Cultured on Biodegradable Microspherical Polymer Scaffolds,” Journal of Biomedical Materials Research Part B: Applied Biomaterials, 75(2…
[cited by applicant]
Kirov, Sergei A. et al. “In Vivo 2-Photon Microscopy Reveals G-CSF Enhanced Mobilization and Targeting of Neo-Endogenous Bone Marrow Stromal Cells to Stroke Injury Sites.” Stroke, Apr. 2009, 40(4): 1-2, e133, Abstract N…
[cited by applicant]
Kitahara, Tatsuro et al. “High-Mobility Group Box 1 Restores Cardiac Function After Myocardial Infarcation in Transgenic Mice,” Cardiovascular Research, European Society of Cardiology, 80: 40-46, Oct. 1, 2008.
[cited by applicant]
Tagami, Kozo et al. “Elevation of serum high-mobility group box 1 protein during granulocyte colony-stimulating factorinduced peripheral blood stem cell mobilisation.” British Journal of Haematology, 135(4): 567-569, (Y…
[cited by applicant]
Tagliafico, Enrico et al. “TGFB/BMP activate the smooth muscle/bone differentiation programs in mesoangioblasts.” Journal of Cell Science, 117(19): 4377-4388, (Year: 2004).
[cited by applicant]
Takahashi, Kunihiko et al. “Modulated Inflammation by Injection of High-Mobility Group Box 1 Recovers Post-Infarction Chronically Failing Heart.” Circulation, 118(14 Suppl): S106-S114, (Year: 2008).
[cited by applicant]
Takahashi, K. et al., “Effects of HMGB1 on PostInfarction Chronic Heart Failure—Novel Mechanism Regarding Therapeutic Effects of Cell Therapy.” Supplement, 27 I-E-19:S189, (Year: 2011).
[cited by applicant]
Takami, Yoichiro et al. “Synergistic induction of hepatocyte growth factor in human skin fibroblasts by the inflammatory cytokines interleukin-1 and interferon-y.” Biochemical and Biophysical Research Communications, 32…
[cited by applicant]
Takeishi, Yasuchika et al. “Importance of Inflammation and Immune Response in Heart Failure—Toll-Like Receptor-Mediated Signaling Pathway and Ventricular Remodeling After Myocardial Infarction.” Journal of Clinical and …
[cited by applicant]
Tamai, Katsuto et al. U.S. Appl. No. 11/997,475, “Mesenchymal Stem Cell Inducer, Tissue Regeneration Promoter and Method of Preparing Mesenchymal Stem Cell.” filed Jan. 31, 2008.
[cited by applicant]
Tamai et al., “Nihon Hiuka Gakkai Zasshi,” Japanese Journal of Dermatology, 2008, 118(4): 645 (#EL28-4) (translated English abstract attached, titled “New Wave of Wound Healing”).
[cited by applicant]
Tamai, K. et al., “PDGFRα-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate inured epithelia,” Proceedings of the National Academy of Sciences, 108(16): 6609-6614, (Apr. 19, …
[cited by applicant]
Tamai, K. et al., “Development and Outlook of Internal Regeneration-Inducing Pharmaceuticals that use in vivo Bone Marrow Mesenchymal Stem / Progenitor Cell-Mobilizing Factors,” Gene & Medicine MOOK, Jul. 22, 2012, pp. …
[cited by applicant]
Tamai, K., “Development of Regeneration-Inducing Medicine Utilizing Molecular Mechanism for in vivo tissue Regeneration by Circulating Mesenchymal Stem Cells.” BIO Clinica, 2016, 31(10): 1042-1046.
[cited by applicant]
Tamai, K. et al., U.S. Appl. No. 17/517,967, “Agents for Promoting Tissue Regeneration by Recruiting Bone Marrow Mesenchymal Stem Cells and/or Pluripotent Stem Cells into Blood .” filed Nov. 3, 2021.
[cited by applicant]
Tamai, K. et al., U.S. Appl. No. 16/768,654, “Therapeutic Agent for Inflammatory Bowel Disease.” filed May 30, 2020.
[cited by applicant]
Tamai, Katsuto et al. U.S. Appl. No. 17/995,017, “Peptide having Mesenchymal Stem Cell Mobilizing Activity.” filed Sep. 29, 2022.
[cited by applicant]
Tamai, Katsuto et al. U.S. Appl. No. 18/069,421, “Peptide for Inducing Regeneration of Tissue and use Thereof.” filed Dec. 21, 2022.
[cited by applicant]
Tamai, Katsuto et al. U.S. Appl. No. 18/152,249, “Pharmaceuticals That Promote Functional Regeneration of Damaged Tissues.” filed Jan. 10, 2023.
[cited by applicant]
Tamilselvi, E., et al., “Association of Disease Severity with IL-1 Levels in Methotrexate-Treated Psoriasis Patients.” Scandinavian Journal of Immunology, 78: 545-553, (Year: 2013).
[cited by applicant]
Tang, Liping & Eaton, John W. “Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials.” J. Exp. Med., 178: 2147-2156, (Year: 1993).
[cited by applicant]
Tang, Daolin et al. “High-Mobility Group Box 1, Oxidative Stress, and Disease.” Antioxidants & Redox Signaling, 14(7): 1315-1335, (Year: 2011).
[cited by applicant]
Taniguchi, Noboru et al. “Stage-Specific Secretion of HMGB1 in Cartilage Regulates Endochondral Ossification.” Molecular and Cellular Biology, 27(16):5650-5664, (Year:2007).
[cited by applicant]
Tao, Aibin et al. “Cardiomyocyte-Fibroblast Interaction Contributes to Diabetic Cardiomyopathy in Mice: Role of HIMGB1/TLR4/IL-33 Axis.” Biochimica et Biophysica Acta, 1852: 2075-2085, (Year: 2015).
[cited by applicant]
Tatsumi, Ryuichi et al. “HGF/SF Is Present in Normal Adult Skeletal Muscle and Is Capable of Activating Satellite Cells,” Developmental Biology, 194: 114-128, (Year: 1998).
[cited by applicant]
Telusma, Gloria et al. “Dendritic cell activating peptides induce distinct cytokine profiles,” International Immunology, 18(11): 1563-1573, (Year: 2006).
[cited by applicant]
Teoh, N., et al., “Low-Dose TNF-Alpha Protects Against Hepatic Ischemia-Reperfusion Injury in Mice: Implications for Preconditioning.” Hepatology, 37(1): 118-128, (Year: 2003).
[cited by applicant]
Thorey, Irmgard S. et al. “The Ca2+ -binding Proteins S100A8 and S100A9 Are Encoded by Novel Injury-regulated Genes*.” Journal of Biological Chemistry, 276(38): 35818-35825, (Year: 2009).
[cited by applicant]
Tokuriki, Nobuhiko et al. “Stability Effects of Mutations and Protein Evolvability.” Current Opinion in Structural Biology, 19: 596-604, (Year: 2009).
[cited by applicant]
Tsung, Allen et al. “Hepatic Ischemia/Reperfusion Injury Involves Functional TLR4 Signaling in Nonparenchymal Cells.” The Journal of Immunology, 175(11): 7661-7668, (Year: 2005).
[cited by applicant]
Türker, Selcan et al. “Nasal route and drug delivery systems.” Pharmacy World and Science, 26: 137-142, (Year: 2004).
[cited by applicant]
Uchida et al. “Nihon Seikei Geka Gakkai Zasshi,” The Journal of Japanese Orthopaedic Surgical Society, 2005, 79(8): S832, 1-P6-6. (English translation attached, titled “The chemotactic activity of PDGF-bb BMP-2, and FGF…
[cited by applicant]
Ueta, Mayumi et al. “Intracellularly Expressed TLR2s and TLR4s Contribution to an Immunosilent Environment at the Ocular Mucosal Epithelium.” The Journal of Immunology, 173(5): 3337-3347, (Year: 2004).
[cited by applicant]
Ulloa, Luis et al. “High-mobility group box 1 (HMGB1) protein: Friend and foe,” Cytokine & Growth Factor Reviews, 17: 189-201, (Year: 2006).
[cited by applicant]
Uronen-Hansson, Heli et al. “Toll-like Receptor 2 (TLR2) and TLR4 are Present Inside Human Dendritic Cells, Associated with Microtubules and the Golgi Apparatus but are not Detectable on the Cell Surface: Integrity of M…
[cited by applicant]
User Manual for StemCell Technologies, “Enumeration, Expansion, and Differentiation of Human Mesenchymal Progenitor Cells Using MesenCult.” StemCell Technologies, Version 2.2.0, (Year: 2007).
[cited by applicant]
Vandal, Karen et al. “Blockade of S100A8 and S100A9 Suppresses Neutrophil Migration in Response to Lipopolysaccharide.” The Journal of Immunology, Sep. 1, 171(5): 2602-2609, (Year: 2003).
[cited by applicant]
Venereau, Emilie et al. “Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release.” The Journal of Experimental Medicine, 209(9): 1519-1528, (Year: 2012).
[cited by applicant]
Walfish, Aaron, E. et al. “Crohn Disease (Regional Enteritis; Granulomatou Ileitis; Granulomatous Ileocolitis).” Merck Manual Professional Version, pp. 1-7, (Year: 2020).
[cited by applicant]
Walfish, Aaron, E. et al. “Overview of Inflammatory Bowel Disease,” Merck Manual Professional Version, pp. 1-3, (Year: 2020).
[cited by applicant]
Walfish, Aaron, E. et al. “Ulcerative Colitis,” Merck Manual Professional Version, pp. 1-8, (Year: 2020).
[cited by applicant]
Wang, H. et al. “HMG-1 as a Late Mediator of Endotoxin Lethality in Mice,” Science, 285(5425): 248-251, (Year: 1999).
[cited by applicant]
Wang, L. et al. “Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture,” Experimental Hematology, 30: 831-836, (2002).
[cited by applicant]
Wang, H. et al., “Kansaibou no riron to gijutu,” Science Press, 5: 58-61 (English translation attached, titled “Theories and Technologies for Stem Cells”), (Year: 2005).
[cited by applicant]
Wang, Haichao et al. “High mobility group protein B1 and the research progress of its biological effect,” Journal of Chinese Modern Surgery, 3(22): 1806-1809 (English translation attached), Jul. 9, 1999.
[cited by applicant]
Wang, H. Y., et al. “Rate of Evolution in Brain-Expressed Genes in Humans and Other Primates.” PLoS Biol., 5(2): e13, (Year: 2007).
[cited by applicant]
Wang, Y., “Biology of hematopoietic stem cell and the research method therof,” Science Press, 1st Edition, pp. 56-58, (Year: 2007).
[cited by applicant]
Wang, W. et al., “Intravenous administration of bone marrow mesenchymal stromal cells is safe for the lung in a chronic myocardial infarction model,” Regen Med, 6(2): 179-190, (Year: 2011).
[cited by applicant]
Wang, Fu-Cai et al. “Overexpression of HMGB1 A-box reduced lipopolysaccharide-induced intestinal inflammation via HMGB1/TLR4 signaling in vitro.” World J Gastroenterol, 21(25): 7764-7776, Jul. 7, 2015.
[cited by applicant]
Watanabe, Taiji et al. “The Role of HMGB-1 on the Development of Necrosis During Hepatic Ischemia and Hepatic Ischemia/Reperfusion Injury in Mice.” Journal of Surgical Research, 124: 59-66, (Year: 2005).
[cited by applicant]
Weintraub, Robert G. et al. “Dilated cardiomyopathy.” The Lancet 390.10092:400-414, Feb. 9, 2017.
[cited by applicant]
Wexler, Sarah A. et al., “Adult Bone Marrow is a Rich Source of Human Mesenchymal ‘Stem’ Cells but Umbilical Cord and Mobilized Adult Blood are Not,” British Journal of Haematology, 121(2): 368-374, (Year: 2003).
[cited by applicant]
Whisstock, James C. et al. “Prediction of Protein Function from Protein Sequence and Structure.” Quarterly Reviews of Biophysics, 36(3): 307-340, (Year: 2003).
[cited by applicant]
Koç, ON et al. “Mesenchymal Stem Cells: Heading into the Clinic,” Bone Marrow Transplantation, 27(3): 235-239, (Year: 2001).
[cited by applicant]
Kohno, T. et al. “High Mobility Group Box 1 Protein is Associated With Post-Infarction Healing Process and Left Ventricular Remodeling.” Circ. J., 2008, 72, Supplement 1, p. J-004: 510-511.
[cited by applicant]
Kokkola, R. et al. “RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages.” Scandinavian Journal of Immunology, 61: 1-9, (Year: 2005).
[cited by applicant]
Komurasaki, Y. et al., “555 Systemic HMGB1 Administration Ameliorated Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Bone Marrow-Derived Mesenchymal Stem Cells to the Lesion.” Journal of Investigative Derm…
[cited by applicant]
Komurasaki, Y., et al., “HMGB1 Ameliorates Bleomycin-Induced Skin Fibrosis by Promoting Accumulation of Mesenchymal Stem Cells to the Lesion.” The 48th Annual Meeting of the Japanese Society of Matrix Biology and Medici…
[cited by applicant]
Koren-Morag, Nira et al. “White Blood Cell Count and the Incidence of Ischemic Stroke in Coronary Heart Disease Patients.” The American Journal of Medicine, 118: 1004-1009, (Year: 2005).
[cited by applicant]
Laflamme, Michael A. et al. “Regenerating the heart,” Nature Biotechnology, 23(7): 845-856, Jul. 7, 2005.
[cited by applicant]
Lanza, Robert et al. “Essentials of Stem Cell Biology —Chapter 27, Mesenchymal Stem Cells,” Elsevier Academic Press, pp. 205-210, (Year: 2006).
[cited by applicant]
La Rosa, T.J. et al., “Glycine max protein Seq ID No: 211221,” Geneseq Accession No. AFQ20044, Oct. 18, 2007.
[cited by applicant]
Lee, Geoffrey et al. “Fully reduced HMGB1 accelerates the regeneration of multiple tissues by transitioning stem cells to Galert.” Proceedings of the National Academy of Sciences, 115(19): E4463-E4472, Apr. 19, 2018.
[cited by applicant]
Lemp, Michael A. et al. “The Definition and Classification of Dry Eye Disease: Report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007).” The Ocular Surface, 5(2): 75-92, (Ye…
[cited by applicant]
Liao, Dan et al. “Vascular smooth cell proliferation in perfusion culture of porcine carotid arteries.” Biochemical and biophysical research communications 372(4): 668-673, Aug. 8, 2008.
[cited by applicant]
Li, S. et al. “Millennium Review, Nonviral gene therapy: promises and challenges,” Gene Therapy 7: 31-34, (Year: 2000).
[cited by applicant]
Li, Zihai et al. “Heat-Shock Proteins,” Current Protocols in Immunology, Supplement 58, A.IT.1-A.IT.6, (Year: 2003).
[cited by applicant]
Li, Ying et al. “Advancement of Human Multiply, Sex health and Reproductive Medical Science,” Peking University Medical Press, Mar. 2007, 1st Edition, pp. 270-271.
[cited by applicant]
Li, Liu-Cheng et al. “Emerging Role of HMGB 1 in Fibrotic Diseases.” Journal of Cellular and Molecular Medicine, 18(12): 2331-2339, (Year: 2014).
[cited by applicant]
Limana, Federica et al. “Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation,” Circulation Research, 97(8): e73…
[cited by applicant]
Limana, Federica et al. “HMGB1 Attenuates Cardiac Remodelling in the Failing Heart via Enhanced Cardiac Regeneration and miR-206-Mediated Inhibition of TIMP-3.” PLoS One, 6(6): e19845, pp. 1-11, Jun. 22, 2011.
[cited by applicant]
Lin, Siang-Yo. et al., “The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells.” Experimental Cell Research, 314(17): 3107-3117, (Year: 2008).
[cited by applicant]
Liotta, Francesco et al. “Toll-Like Receptors 3 and 4 Are Expressed by Human Bone Marrow-Derived Mesenchymal Stem Cells and Can Inhibit Their T-Cell Modulatory Activity by Impairing Notch Signaling.” Stem Cells, 26(1): …
[cited by applicant]
Liu, Ke-Xin et al. “Human Placental Extract Stimulates Liver Regeneration in Rats,” Biological and Pharmaceutical Bulletin, 21(1): 44-49, (Year: 1998).
[cited by applicant]
Lonza BenchGuides_Poietics hMSC Human Mesenchymal Stem Cells and Media (Document # TS-PT-212-7 04/08), 2008, Walkersville, MD, USA.
[cited by applicant]
Lotze, Michael T. “High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.” Nature Reviews Immunology 5(4):331-342, (Year: 2005).
[cited by applicant]
Lund, Lars H. et al. “The Registry of the International Society for Heart and Lung Transplantation: Thirty-Third Adult Heart Transplantation Report—2016; Focus Theme: Primary Diagnostic Indications for Transplant.” The …
[cited by applicant]
Mansbridge, Jonathan et al. “Skin Tissue Engineering.” J. Biomater, Sci. Polymer, Ed., 19(8): 955-968, (Year: 2008).
[cited by applicant]
Maron, Barry J. et al. “Contemporary Definitions and Classification of the Cardiomyopathies—an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation C…
[cited by applicant]
Martin-Murphy, Brittany V. et al. “The Role of Damage Associated Molecular Pattern Molecules in Acetaminophen-Induced Liver Injury in Mice.” Toxicol Lett, 192(3): 1-20, Feb. 15, 2010.
[cited by applicant]
Maruyama, I. “Inflammation and HMGB1/RAGE system.” Kekkan Igaku, 2005, 6(5): 519-525 (English translation attached).
[cited by applicant]
Matsumoto, Kunio et al. “Up-Regulation of Hepatocyte Growth Factor Gene Expression by Inerleukin-1 in Human Skin Fibrosis, ” Biochemical and Biophysical Research Communications, 188(1): 235-243, Oct. 15, 1992.
[cited by applicant]
Meng, Er-Hong et al. “HMGB1 induces migration of human bone marrow-derived mesenchymal stem cells.” Bulletin of the Academy of Military Medical Sciences, 30(3): 213-216 (English translation attached), (Year: 2006).
[cited by applicant]
Meng, Erhong et al. “High Mobility Group Box 1 Protein Inhibits the Proliferation of Human Mesenchymal Stem Cells and Promotes Their Migration and Differentiation along Osteoblastic Pathway.” Stem Cells and Development,…
[cited by applicant]
Merenmies, Jussi et al. “30-kDa Heparin-binding Protein of Brain (Amphoterin) Involved in Neurite Outgrowth.” Journal of Biological Chemistry, 266(25): 16722-16729, Sep. 5, 1991.
[cited by applicant]
Mistry, A.R. et al., “Recombinant HMG1 Protein Produced in Pichia pastoris: A Nonviral Gene Delivery Agent.” Biotechniques, 22(4): 718-729, (Year: 1997).
[cited by applicant]
Mori, T. et al., “Stem Cells/ES cells—Mesenchymal Stem Cells—Human Bone Marrow Derived Mesenchymal Stem Cells,” Saisei Iryou—Regenerative Medicine, 2005, 4(3): 421-429, 351.
[cited by applicant]
Morikawa, Satoru et al. “Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in urine bone marrow.” The Journal of Experimental Medicine 206(11):2483-2496, (Year: 20…
[cited by applicant]
Morosetti, Roberta et al. “MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle.” PNAS, 103(45): 16995-17000, Nov. 7, 2006.
[cited by applicant]
Mouse care guidance from the Institutional Animal Care and Use Committee at University of California, San Francisco; acuc.ucsf.edu/Policies/BloodCollectionMice.doc; accessed May 15, 2014.
[cited by applicant]
Muhamed, Jaseer et al. “Phenotypic Modulation of Cell Types around Implanted Polyethylene Terephthalate Fabric in Rabbit Muscle.” Toxicologic Pathology, 41: 497-507, (Year: 2013).
[cited by applicant]
Muhammad, Sajjad et al. “The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage.” The Journal of Neuroscience, 28(46): 12023-12031, Nov. 12, 2008.
[cited by applicant]
Müller, Susanne et al., “The double life of HMGB1 chromatin protein: architectural factor and extracellular signal,” EMBO Journal, 20(16): 4337-4340, (Year: 2001).
[cited by applicant]
Musumeci, Domenica et al. “An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies.” Pharmacology & Therapeutics, 141: 347-357, (Year: 2014).
[cited by applicant]
Nakajima et al., “Dynamics and Role of High Mobility Group Box-1 (HMGB-1) in Injured Spinal Cord,” Nihon Seikei Geka Gakkai Zasshi (J. Jpn. Orthop. Assoc.), 84(8): S1050, (Year: 2010).
[cited by applicant]
Nakamura, Koji et al. “p38 Mitogen-Activated Protein Kinase Functionally Contributes to Chondrogenesis Induced by Growth/Differentiation Factor-5 in ATDC5 Cells,” Experimental Cell Research, 250(2): 351-363, (Year: 1999…
[cited by applicant]
Nakanishi, Shigetada et al., “Membrane Potential-Regulated Ca2+ Signalling in Development and Maturation of Mammalian Cerebellar Granule Cells.” J. Physiol., 575(2): 389-395, (Year: 2006).
[cited by applicant]
Narumi, Taro et al. “Abstract 15265: Cardiac-specific Overexpression of High-Mobility Group Box 1 Protects Cardiomyocyte from Apoptosis During the Pathogenesis of Doxorubicin Cardiomyopathy.” Circulation, 126:A15265, Ma…
[cited by applicant]
Narumi, T., et al., “High-mobility Group Box 1 Attenuates Mitochondrial Dysfunction and Apoptosis via Heat Shock Protein Beta 1 Induction in Doxorubicin-induced Cardiomyopathy.” Bulletin of Yamagata University (Medical …
[cited by applicant]
Narumi, T., et al., “High-Mobility Group Box 1-Mediated Heat Shock Protein Beta 1 Expression Attenuates Mitochondrial Dysfunction and Apoptosis.” Journal of Molecular and Cellular Cardiology, 82: 1-12, (Year: 2015).
[cited by applicant]
NCBI, “Old myocardial infarction.” MedGen UID: 57612, retrieved from internet Jan. 19, 2022, <https://www.ncbi.nlm.nih.gov/medgen/57612>.
[cited by applicant]
Nickoloff, Brian J. & Nestle, Frank O. “Recent Insights into the Immunopathogenesis of Psoriasis Provide new Therapeutic Opportunities.” J. Clin. Invest., 113(12): 1664-1675, (Year: 2004).
[cited by applicant]
Nojiri, Shunsuke et al. “Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.” Inflammation and Regeneration 41(28):1-15, (Year: 2021).
[cited by applicant]
WHO Drug Information, vol. 32, No. 1, Appendix 5, p. 155, (Year: 2018).
[cited by applicant]
Wilgus, Tracy A. et al.“Neutrophils and wound repair: positive actions and negative reactions.” Advances in wound care 2.7: 379-388, (Year: 2013).
[cited by applicant]
Witkowski, Andrzej et al. “Conversion of a β-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine.” Biochemistry, 38: 11643-11650, (Year: 1999).
[cited by applicant]
Wolf, Gunter et al. “From the Periphery of the Glomerular Capillary Wall Toward the Center of Disease.” Diabetes, 54(6): 1626-1634, (Year: 2005).
[cited by applicant]
Woodbury, Dale et al. “Adult Rat and Human Bone Marrow Stromal Cells Differentiate into Neurons.” Journal of Neuroscience Research, 61(4): 364-370, Aug. 15, 2000.
[cited by applicant]
Wu, Yaojiong et al. “Mesenchymal Stem Cells Enhance Wound Healing Through Differentiation and Angiogenesis,” Stem Cells, 25(10): 2648-2659. Epub Jul. 5, 2007.
[cited by applicant]
Wynn, Thomas A. & Ramalingam, Thirumalai R. “Mechanisms of fibrosis: therapeutic translation for fibrotic disease.” Nat Med. 18(7): 1028-1040, (Year: 2013).
[cited by applicant]
Yamada, Takayuki et al. “Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells,” Blood, 101(6): 2227-2234, (Year: 2003).
[cited by applicant]
Yamaoka, S. et al. “1043 Systemic delivery of HMGB1 peptide ameliorates imiquimod-induced psoriasis-like dermatitis.” Journal of Investigative Dermatology, 138(5): S177, (Year: 2018).
[cited by applicant]
Yang, Huan et al. “The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis.” J. Leukoc Biol. 93(6): 865-873, (Year: 2013).
[cited by applicant]
Yang, Huan et al. “Reversing established sepsis with antagonists of endogenous high-mobility group box 1.” Proceedings of the National Academy of Sciences, 101(1): 296-301, (Year: 2004).
[cited by applicant]
Yang, Sirui et al. “Does Pretreatment of Bone Marrow Mesenchymal Stem Cells with 5-Azacytidine or Double Intravenous Infusion Improve Their Therapeutic Potential for Dilated Cardiomyopathy?” Medical Science Monitor Basi…
[cited by applicant]
YBOX1_Human, Accession No. P67809, entry version 164, UniProtKB/Swiss-Prot, Sep. 12, 2018.
[cited by applicant]
Youn, Ju Ho et al. “High Mobility Group Box 1 Protein Binding to Lipopolysaccharide Facilitates Transfer of Lipopolysaccharide to CD14 and Enhances Lipoplysaccharide-Mediated TNF-α Production in Human Monocytes,” Journa…
[cited by applicant]
Yuan, Y. et al. “Differentiation of Mesenchymal Stem Cells in Cardiomyogenic Cells Under the Induction of Myocardial Cell Lysate.” Chinese Journal of Cardiology, 33(2): 170-173, (Year: 2005).
[cited by applicant]
Yu, Q. et al. “Impact of Repeated Intravenous Bone Marrow Mesenchymal Stem Cells Infusion on Myocardial Collagen Network Remodeling in a Rat Model of Doxorubicin-Induced Dilated Cardiomyopathy.” Molecular and Cellular B…
[cited by applicant]
Zheng, Xiaoyan et al. “Adeno-associated virus-mediated colonic secretory expression of HMGB1 A box attentuates experimental colitis in mice.” J Gene Med, 18(10): 261-272, (Year: 2016).
[cited by applicant]
Zhao, Ji & Jiang, Hong “The Study Progression of the Role of HMGBI in Ichemic Heart Failure.” MOlecular Cardiology of China, pp. 1169-1171, Dec. 25, 2014.
[cited by applicant]
Zhou, X., et al., “Section 2 The translation process of genetic information.” Molecular Genetics, 1992, pp. 141-143.
[cited by applicant]
Zhou, Xiaoya et al. “Exogenous High-Mobility Group Box 1 Protein Injection Improves Cardiac Function after Myocardial Infarction: Involvement of Wnt Signaling Activation,” Journal of Biomedicine and Biotechnology, vol. …
[cited by applicant]
Zhou, Yan-Hong et al. “High mobility group box 1 protein attenuates myocardial ischemia reperfusion injury via inhibition of the p38 mitogen-activated protein kinase signaling pathway.” Experimental and Therapeutic Medi…
[cited by applicant]
Baer, Patrick C. et al. “Comprehensive Phenotypic Characterization of Human Adipose-Derived Stromal/Stem Cells and Their Subsets by a High Throughput Technology.” Stem Cells and Development 00(00):1-10, (Year: 2012).
[cited by applicant]
Bigazzi, Pierluigi E. & Rose, Noel R. “Introduction to Review Series on Animal Models of Human Disease.” Clinical Immunology and Immunopathology, 74(1): 1, (Year: 1995).
[cited by applicant]
Bretag, Allan “Too much hype, not enough hope: Are balanced reporting and proper controls too much to expect from therapeutic studies in animal models of neuromuscular diseases that presage clinical trials in humans?” N…
[cited by applicant]
He, Yiyu et al. “Exogenous High-Mobility Group Box 1 Protein Prevents Postinfarction Adverse Myocardial Remodeling Through TGF-β/Smad Signaling Pathway.” Journal of Cellular Biochemistry 114: 1634-1641, (Year: 2013).
[cited by applicant]
PROCR gene—Protein C Receptor. Downloaded from https://www.genecards.org/cgi-bin/carddisp.pl?gene=PROCR, accessed Mar. 31, 2023.
[cited by applicant]
Ahrens, Norbert et al. “Mesenchymal Stem Cell Content of Human Vertebral Bone Marrow.” Transplantation 78(6): 925-929, (Year: 2004).
[cited by applicant]
Aikawa, Eriko et al. “HMGB1 accelerates skin regeneration by inducing bone marrow mesenchymal stromal cells.” Journal of Dermatological Science 84(1): 1-14, (Year: 2016).
[cited by applicant]
Alden, T. D., et al. “In Vivo Endochondral Bone Formation Using a Bone Morphogenetic Protein 2 Adenoviral Vector.” Human Gene Therapy, Sep. 1999, 10(13): 2245-2253.
[cited by applicant]
Andersson, Ulf et al. “HMGB1 is a Therapeutic Target for Sterile Inflammation and Infection.” Annu Rev Immunol. 29: 139-162 (Year: 2011).
[cited by applicant]
Andersson, Ulf et al., “HMGB1 as a DNA-binding cytokine.” Journal of Leukocyte Biology, 72: 1084-1091, (Year: 2002).
[cited by applicant]
Andrassy, Martin et al. “High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart.” Circulation 117(25): 3216-3226, (Year: 2008).
[cited by applicant]
Arminan, A. et al., “Mesenchymal Stem Cells Provide Better Results Than Hematopoietic Precursors for the Treatment of Myocardial Infarction.” Journal of the American College of Cardiology, 55(20): 2244-2253, (Year: 2010…
[cited by applicant]
Arnau, J. et al., “Current Strategies for the use of Affinity Tags and Tag Removal for the Purification of Recombinant Proteins.” Protein Expression and Purification, 48: 1-13, (Year: 2006).
[cited by applicant]
Asch, F.M. et al. “Lack of sensitivity of the electrocardiogram for detection of old myocardial infarction: A cardiac magnetic resonance imaging study.” American Heart Journal, 152(4): 742-748, (Year: 2006).
[cited by applicant]
Ball, S.G., et al., “Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors.” J. Cell. Mo. Med., 11(5): 1012-1030, (Year: 2007).
[cited by applicant]
Basso, D. M. et al., “Basso Mouse Scale for Locomotion Detects Differences in Recovery after Spinal Cord Injury in Five Common Mouse Strains.” Journal of Neurotrauma, 23(5): 635-659, (Year: 2006).
[cited by applicant]
Berry, M. F. et al., “Mesenchymal stem cell injection after myocardial infarction improves myocardial compliance.” Am. J. Physiol. Heart Circ. Physiol. 290(6): H2196-H2203, Feb. 10, 2006.
[cited by applicant]
Bhattacharya, Roshni et al. “Impact of genetic variation on three dimensional structure and function of proteins.” PloS one, 12(3): 1-22, Mar. 15, 2017.
[cited by applicant]
Bianchi, M. E., “High mobility group 1 protein (HMGB1) N-terminal peptide.” Geneseq Accession No. ADO80180, Aug. 12, 2004.
[cited by applicant]
Bianchi, M. E. et al., “The DNA binding site of HMG1 protein is composed of two similar segments (HMG boxes), both of which have counterparts in other eukaryotic regulatory proteins.” The EMBO Journal, 11(3):1055-1063, …
[cited by applicant]
Bittira, B. et al., “Mobilization and homing of bone marrow stromal cells in myocardial infarction.” European Journal of Cardio-thoracic Surgery, 24(3): 393-398, (Year: 2003).
[cited by applicant]
Blain, Alison M. & Straub, Volker W. “δ-Sarcoglycan-deficient muscular dystrophy: from discovery to therapeutic approaches.” Skeletal Muscle, 1(13): 1-12, (Year: 2011).
[cited by applicant]
Brunner, S., et al., “Erythropoientin Administration After Myocardial Infarction in Mice Attenuates Ischemic Cardiomyopathy Associated with Enhanced Homing of Bone Marrow-Derived Progenitor Cells Via the CXCR-4/SDF-1 Ax…
[cited by applicant]
BTF3_Human, Accession No. P20290, entry version 166, UniProtKB/Swiss-Prot, Sep. 12, 2018.
[cited by applicant]
Bustin, Michael “Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility-Group Chromosomal Proteins.” Mol. Cell. Biol., 19(8): 5237-5246, (Year: 1999).
[cited by applicant]
Cairo, Mitchell. S. “Results of a Phase I/II Trial of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Very Low Birthweight Neonates: Significant Induction of Circulatory Neutrophils, Monocytes, Pla…
[cited by applicant]
“Cardiomegaly” Merriam Webster, 2015 archived page, accessed via Wayback Machine [online] [accessed at https://web.archive.org/web/20150107154504/https://www.merriam-webster.com/medical/cardiomegaly on May 21, 2020]. (Y…
[cited by applicant]
“Cardiomyopathy: Symptoms, diagnosis and treatment.” Harvard Health Publishing Harvard Medical School, Dec. 29, 2014.
[cited by applicant]
Castro, Raymond. F. et al., “Failure of Bone Marrow Cells to Transdifferentiate into Neural Cells in Vivo.” Science, 297(5585): 1299, Aug. 23, 2002.
[cited by applicant]
Chamberlain, Giselle. et al., “Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing.” Stem Cells, 25: 2739-2749, Jul. 26, 2007.
[cited by applicant]
Chan, James. K., et al. “Alarmins: awaiting a clinical response.” The Journal of Clinical Investigation 122(8):2711-2719, (Year: 2012).
[cited by applicant]
Charoonpatrapong, Kanokwan et al., “HMGB1 Expression and Release by Bone Cells.” Journal of Cellular Physiology, 207(2): 480-490, (Year: 2006).
[cited by applicant]